Review for "The Italian-Canine Cancer (ICC) Biobank: our 10-year challenge"

Author(s):  
Ondrej Skor
Keyword(s):  
2019 ◽  
Vol 17 (2) ◽  
pp. 119-129
Author(s):  
Tatsuya Deguchi ◽  
Kenji Hosoya ◽  
Yusuke Murase ◽  
Sung Koangyong ◽  
Sangho Kim ◽  
...  

2018 ◽  
Vol 55 (6) ◽  
pp. 809-820 ◽  
Author(s):  
Ramona Graf ◽  
Andreas Pospischil ◽  
Franco Guscetti ◽  
Daniela Meier ◽  
Monika Welle ◽  
...  

Data collected in animal cancer registries comprise extensive and valuable information, even more so when evaluated in context with precise population data. The authors evaluated 11 740 canine skin tumors collected in the Swiss Canine Cancer Registry from 2008–2013, considering data on breed, sex, age, and anatomic locations. Their incidence rate (IR) per 100 000 dogs/year in the Swiss dog population was calculated based on data from the official and mandatory Swiss dog registration database ANIS. The most common tumor types were mast cell tumors (16.35%; IR, 60.3), lipomas (12.47%; IR, 46.0), hair follicle tumors (12.34%; IR, 45.5), histiocytomas (12.10%; IR, 44.6), soft tissue sarcomas (10.86%; IR, 40.1), and melanocytic tumors (8.63%; IR, 31.8) with >1000 tumors per type. The average IR of all tumor types across the 227 registered breeds was 372.2. The highest tumor incidence was found in the Giant Schnauzer (IR, 1616.3), the Standard Schnauzer (IR, 1545.4), the Magyar Vizsla (IR, 1534.6), the Rhodesian Ridgeback (IR, 1445.0), the Nova Scotia Duck Tolling Retriever (IR, 1351.7), and the Boxer (IR, 1350.0). Mixed-breed dogs (IR, 979.4) had an increased IR compared to the average of all breeds. Previously reported breed predispositions for most tumor types were confirmed. Nevertheless, the data also showed an increased IR for mast cell tumors and melanocytic tumors in the Nova Scotia Duck Tolling Retriever and for histiocytomas in the Flat Coated Retriever. The results from this study can be taken into consideration when selecting purebred dogs for breeding to improve a breed’s health.


2018 ◽  
Vol 5 (1) ◽  
pp. 19-29
Author(s):  
Atsushi Tanabe ◽  
Daisuke Kobayashi ◽  
Koki Maeda ◽  
Masayuki Taguchi ◽  
Hiroeki Sahara

2018 ◽  
Vol 5 (4) ◽  
pp. 87 ◽  
Author(s):  
Chris Weir ◽  
Annika Oksa ◽  
Jennifer Millar ◽  
Miles Alexander ◽  
Nicola Kynoch ◽  
...  

Canine cancer rates are similar to humans, though the therapeutic options might be limited. Inducing a patient’s own immune system to have an anti-tumor response is an attractive approach to cancer therapy. In this safety study, autologous tumor vaccines produced specifically for each canine patient were combined with Advax™, a novel non-inflammatory immunomodulator and vaccine adjuvant and were tested for safety in a diverse range of patient presentations alone or in combination with other treatments. Canine patients had their tumor biopsied, debulked or resected and the tumor antigens were processed into an autologous vaccine formulated with Advax™ adjuvant with or without rhizavidin as an additional immune stimulant. Patients treated early in the trial received two intramuscular (IM) doses, 2 weeks apart. As the study progressed and no issues of safety were observed, the protocol was changed to weekly vaccinations for 4 weeks followed by monthly booster shots. Over the 150 I.M injections delivered to date, the vaccine was found to be very safe and no significant adverse reactions were observed. These results justify ongoing development and future controlled studies of this autologous vaccine approach.


Author(s):  
Takuro Ishikawa ◽  
Tomohiro Osaki ◽  
Akihiro Sugiura ◽  
Jiro Tashiro ◽  
Tomoko Warita ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document